Olema reports Q3 2026 results, reiterates early-2027 OPERA-01 data timelineNov 16Regulatory decisionOlema Pharmaceuticals, Inc.palazestrant
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
UIC registers Phase 1 trial of Pfizer's elranatamab in plasmablastic lymphomaOct 30Weekly roundup, 11 itemsAstellas Pharmaatirmociclib
Pfizer registers four studies: elranatamab, berobenatide, tilrekimig, and completed etrasimod trialOct 23Weekly roundup, 14 itemsabrocitinibatirmociclibUpdated
Pfizer's Ruxience biosimilar supplement approved; breast cancer trials post resultsSep 30Weekly roundup, 8 itemsatirmociclibberobenatideUpdated
Olema completes OPERA-01 enrollment, pushes top-line data to Q1 2027Aug 10Quarterly updateOlema Pharmaceuticals, Inc.
Pfizer wins four Zithromax label updates in one week; two Phase 2 trial results also postedJul 15Weekly roundup, 6 itemsatirmociclibazithromycin
Pfizer wins five FDA label updates for tofacitinib, ritlecitinib, abrocitinib; Crohn's trial haltedJul 2Weekly roundup, 12 itemsabrocitinibatirmociclib